RICHTER:BETChemical Works of Gedeon Richter Plc Analysis
Data as of 2026-03-11 - not real-time
€30.14
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Gedeon Richter PLC is trading at €30.14, comfortably above the 20‑day SMA (≈30.59) and the 50‑day SMA (≈28.76), confirming a medium‑term bullish bias, while the 200‑day SMA (≈26.48) remains well below the price. The RSI sits at 51, indicating neutral momentum, but the MACD histogram is negative and the MACD line sits beneath its signal, suggesting short‑term bearish pressure as the stock approaches its resistance around €32.24. Volume is on the rise and volatility is elevated at over 45% 30‑day, yet the beta is exceptionally low (≈0.08), meaning price swings are largely company‑specific rather than market‑driven.
Fundamentally, the stock appears markedly undervalued: a trailing P/E of 9.7 versus an industry average of 25.2, and a price‑to‑book of just 0.004, point to a deep discount. The dividend yield of 4.24% with a payout ratio near 42% is supported by strong free cash flow, while revenue is growing at roughly 12½ % and ROE sits at 17 %. Although the debt‑to‑equity ratio is high, the low beta and robust cash generation mitigate financial risk, making the stock attractive for value‑oriented investors.
Fundamentally, the stock appears markedly undervalued: a trailing P/E of 9.7 versus an industry average of 25.2, and a price‑to‑book of just 0.004, point to a deep discount. The dividend yield of 4.24% with a payout ratio near 42% is supported by strong free cash flow, while revenue is growing at roughly 12½ % and ROE sits at 17 %. Although the debt‑to‑equity ratio is high, the low beta and robust cash generation mitigate financial risk, making the stock attractive for value‑oriented investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- MACD bearish divergence despite overall uptrend
- Proximity to resistance level at €32.24
- High 30‑day volatility coupled with rising volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation discount (P/E 9.7 vs industry 25.2)
- Strong dividend yield with sustainable payout
- Revenue growth of ~12.5% and solid ROE
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Consistently low beta indicating defensive profile
- Robust free cash flow supporting dividend continuity
- Strategic product pipeline and diversified healthcare exposure
Key Metrics & Analysis
Financial Health
Revenue Growth12.50%
Profit Margin25.01%
P/E Ratio9.7
ROE17.17%
ROA11.15%
Debt/Equity6.97
P/B Ratio0.0
Free Cash Flow€162.4B
Industry P/E25.2
Technical Analysis
TrendBullish
RSI51.4
Support€28.00
Resistance€32.24
MA 20€30.59
MA 50€28.76
MA 200€26.48
MACDBearish
VolumeIncreasing
Fear & Greed Index78.16
Valuation
Fair Value€20,793.30
GradeUndervalued
TypeBlend
Dividend Yield4.24%
Risk Assessment
Beta0.08
Volatility45.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.